| 2026-08-12 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Travere Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-08-04 | Fact sheet | Investor Fact Sheet |
| 2026-08-04 | Press release | Press Release |
| 2026-07-28 | Press release | Travere Therapeutics to Report Second Quarter 2026 Financial Results |
| 2026-07-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-16 | Press release | Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 |
| 2026-06-11 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-04 | Press release | View PDF , Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd E |
| 2026-06-02 | Press release | Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Bes |
| 2026-05-27 | Press release | Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application |
| 2026-05-13 | Press release | Travere Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-05-12 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-10 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-07 | Press release | View PDF , Travere Therapeutics to Participate at Upcoming Investor Conferences, May 7, 2026, (opens in new window) |
| 2026-05-06 | Press release | View PDF , Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes, |
| 2026-05-05 | Press release | View PDF , Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes, May 5, 2026 |
| 2026-05-04 | Document | Travere Therapeutics Reports First Quarter 2026 Financial Results |
| 2026-05-04 | Fact sheet | Investor Fact Sheet
of Q1 2026, PDF file, (opens in new window) |
| 2026-05-04 | Press release | Press Release
of Q1 2026, PDF file, (opens in new window) |
| 2026-04-27 | Press release | Travere Therapeutics to Report First Quarter 2026 Financial Results |
| 2026-04-14 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-13 | Press release | View PDF , Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medic |
| 2026-02-19 | Press release | Press Release |
| 2026-02-18 | Fact sheet | Investor Fact Sheet |
| 2026-02-12 | Press release | Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-11 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-04 | Press release | View PDF , Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit, February 4, 2026, (opens i |
| 2026-01-13 | Press release | View PDF , Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS, January 13, 202 |
| 2026-01-12 | Press release | View PDF , Travere Therapeutics Provides Corporate Update and 2026 Outlook, January 12, 2026, (opens in new window) |
| 2026-01-05 | Press release | View PDF , Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference, January 5, 2026, (opens |
| 2025-10-29 | Fact sheet | Investor Fact Sheet |
| 2025-05-12 | Press release | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-05-01 | Press release | Travere Therapeutics Reports First Quarter 2025 Financial Results |
| 2025-04-29 | Press release | Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI<sup>®</sup> (sparsentan) for IgA Nephro |
| 2025-04-24 | Press release | Travere Therapeutics to Report First Quarter 2025 Financial Results |
| 2025-03-31 | Press release | Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetin |
| 2025-02-20 | Press release | Q4 |